Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination

Seiji Kobayashi; Kazunori Fugo; Ryo Hatano; Kazuto Yamazaki; Chikao Morimoto; Hiroyuki Terawaki

doi:10.2169/internalmedicine.1027-22

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination

Seiji Kobayashi, Kazunori Fugo, Ryo Hatano, Kazuto Yamazaki, Chikao Morimoto, Hiroyuki Terawaki

著者情報

キーワード: Anti-GBM disease, ANCA-associated glomerulonephritis, IL-26, mRNA-based COVID-19 vaccine, pharmacovigilance

ジャーナルオープンアクセス早期公開

論文ID: 1027-22

DOI https://doi.org/10.2169/internalmedicine.1027-22

この記事には本公開記事があります。

The final version of this article is now available: Vol. 62 (2023), No. 7 pp. 1043-1048

詳細

抄録

As coronavirus disease 2019 (COVID-19) vaccine booster campaigns progress worldwide, new reports of complications following COVID-19 vaccination have emerged. We herein report a case of new-onset anti-glomerular basement membrane (GBM) disease concomitant with myeloperoxidase-antineutrophil cytoplasmic antibody positivity concurrent with high levels of interleukin (IL)-26 following the second dose of the Pfizer-BioNTech COVID-19 vaccine. The temporal association with vaccination in this case suggests that an enhanced neutrophilic immune response through IL-26 may have triggered necrotizing glomerulonephritis and a T-cell-mediated immune response to GBMs, leading to the development of anti-GBM antibodies, with an enhanced B-cell response after the vaccination triggering anti-GBM IgG and the onset of anti-GBM disease.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）